[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658756":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":18,"armGroups":28,"interventions":41,"overallOfficials":18,"centralContacts":51,"locations":57,"responsibleParty":75,"collaborators":18,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":18,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":18,"enrollmentInfo":87,"targetDuration":18,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":60,"whyStopped":18,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Mansoura University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"treatment failure","treatment failure defined as the need for escalation from assigned respiratory support to a higher level of ventilatory support during hospitalization. In HFNC group, treatment failure is defined as the need for rescue NIV or invasive mechanical ventilation. In the NIV group ,treatment failure is defined as the need of invasive mechanical ventilation.\n\n( number and percentages of patients experiencing treatment failure in each treatment group)","From initiation of the assigned respiratory support until hospital discharge, assessed throughout the hospitalization (up to 30 days).",[14],{"measure":15,"description":16,"timeFrame":17},"serial arterial blood gas parameters at 12, 24 and 48 hours","serial arterial blood gas parameters (pH, PaCO2, HCO3) at 12, 24 and 48 hours;","at 12, 24, 48 hours after start of respiratory support",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":24,"maskingDescription":18,"whoMasked":25},"DOUBLE",[26,27],"PARTICIPANT","INVESTIGATOR",[29,35],{"label":30,"type":31,"description":32,"interventionNames":33},"Arm 1: high flow nasal canula","EXPERIMENTAL","patients recieve high flow nasal canula oxygen therapy according to study protocol",[34],"Device: high flow nasal cannula",{"label":36,"type":37,"description":38,"interventionNames":39},"Arm 2: non invasive ventilation (NIV)","ACTIVE_COMPARATOR","patients recieve NIV according to study protocol",[40],"Device: non invasive ventilation",[42,47],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":18},"DEVICE","high flow nasal cannula","high flow nasal canula oxygen therapy according to study protocol",[30],{"type":43,"name":48,"description":49,"armGroupLabels":50,"otherNames":18},"non invasive ventilation","non invasive ventilation according to study protocol",[36],[52],{"name":53,"role":54,"phone":55,"phoneExt":18,"email":56},"Mohammed Shehta, associate professor-chest med.","CONTACT","01004344106","dr_mshehta@mans.edu.eg",[58],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Faculty of Medicine, Mansoura University","RECRUITING","Al Mansurah","Dakahlia Governorate","35516","Egypt","EG",{"type":67,"coordinates":68},"Point",[69,70],31.38069,31.03637,{"lat":70,"lon":69},[73],{"name":74,"role":54,"phone":18,"phoneExt":18,"email":56},"Mohammed Shehta",{"type":76,"investigatorFullName":74,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Associate professor of chest medicine","100658756","hfnc-versus-niv-in-hypercapneic-copd-patients-100658756",false,"NCT07854210","HFNC Versus NIV in Hypercapneic COPD Patients","Gas Exchange, Clinical Outcomes, and Tolerability of High-Flow Nasal Cannula Versus Non-Invasive Ventilation in COPD Patients With Mild-to-Moderate Hypercapnic Respiratory Failure","Inclusion Criteria:\n\n* COPD patients hospitalized with mild-to-moderate hypercapnic respiratory failure, defined as arterial pH \\[range, e.g., 7.25-7.35\\] and PaCO2 \\[threshold, e.g., \\>45 mmHg and less 60 mmHg\\].\n\nExclusion Criteria:\n\n* patients with altered mental state, confused, severe agitation or not cooperative were excluded. Also, severe acidosis (pH \\\u003C7.25), hemodynamic instability, facial trauma or surgery, cases with severe nasal deformity, immediate indication for invasive ventilation, patient refusal, cases with respiratory rate more than 35 breaths per minute. Respiratory exhaustion, excess use of respiratory accessory muscles, Patients with breathing disorders during sleep as well as cases of upper airway obstruction and patients with history of chronic home ventilation prior admission were another items for exclusion","ALL","40 Years",{"count":88,"type":89},70,"ESTIMATED","INTERVENTIONAL",[92],"NA","Aim: To compare gas exchange trends, clinical outcomes, and tolerability between HFNC and NIV in COPD patients with mild-to-moderate hypercapnic respiratory failure.",[95],"COPD (Chronic Obstructive Pulmonary Disease)",[97,98,99,100],"COPD","Hypecapneic respiratory failure","HFNC","NIV","2026-10-01",{"date":103,"type":104},"2026-10-02","ACTUAL",{"date":106,"type":104},"2025-11-03",{"date":108,"type":89},"2026-12",{"name":74,"class":6},1]